{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.47","upperLimit":"0.98","value":"0.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"GMI defined as the ratio of Time to Progression (TTP) with the nth line of therapy (TTPn; here defined as milademetan) to the most recent prior line of therapy (TTPn-1)","dispersionType":"Inter-Quartile Range","groups":[{"description":"260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle","id":"OG000","title":"Milademetan (RAIN-32)"}],"paramType":"MEDIAN","populationDescription":"The efficacy analysis is conducted in all participants within the Centrally confirmed population (CCP).","reportingStatus":"POSTED","timeFrame":"From the start date of the most recent prior line of therapy to the PD date on the study; up to 23.5 months","title":"Growth Modulation Index (GMI)","type":"SECONDARY","unitOfMeasure":"months"}